Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2022 Results - Earnings Call Transcript
10:15pm, Tuesday, 10'th May 2022
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Susan Hubbard - EVP of Public Affairs and IR Mike Morrissey - President and CEO Chris Senner
Exelixis (EXEL) Tops Q1 Earnings Estimates
09:25pm, Tuesday, 10'th May 2022 Zacks Investment Research
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Tops Q1 Earnings Estimates
06:49pm, Tuesday, 10'th May 2022
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Sector ETF report for FBT
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
03:37pm, Monday, 09'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Why Exelixis (EXEL) Might Surprise This Earnings Season
12:48pm, Monday, 09'th May 2022 Zacks Investment Research
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
12:47pm, Monday, 09'th May 2022
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Why Exelixis (EXEL) Might Surprise This Earnings Season
10:32am, Monday, 09'th May 2022
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
10:20am, Friday, 06'th May 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
10:20am, Wednesday, 04'th May 2022 Zacks Investment Research
Sector ETF report for XBI
3 Growth Stocks to Buy With $1,000 Right Now
02:00pm, Tuesday, 03'rd May 2022 The Motley Fool
A small investment can go a long way.
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
01:40pm, Friday, 29'th Apr 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Much You'd Have If You Invested $1000 in Exelixis a Decade Ago
12:30pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
